Vomiting: What Could Be Causing It
A clinical guide to the most common and serious causes of vomiting, how physicians diagnose the underlying trigger, and when to seek emergency care.
Vomiting: Labs, Diagnosis, and Next Steps
A clinical guide to the laboratory workup, diagnostic evaluation, and evidence-based next steps for persistent or unexplained vomiting in adults.
Medicine Causing Vomiting: Which Drugs and Why
Opioids, chemo agents, SSRIs and antibiotics can trigger vomiting. See which drugs cause it and which antiemetics, like ondansetron, treat it.
Vomiting: When to See a Doctor and What Causes It
Learn what causes vomiting, how it is diagnosed, effective treatments, and the specific warning signs that mean you should see a doctor right away.
Weak Urine Stream: When to See a Doctor and What It Could Mean
A weak urinary stream can signal BPH, urethral stricture, or neurogenic bladder. Learn the red flags, diagnostic workup, and treatment options that warrant medical evaluation.
Drugs That Cause or Treat Weight Gain
A clinical guide to medications linked to weight gain and FDA-approved pharmacotherapies for weight management, including GLP-1 receptor agonists, antipsychotics, corticosteroids, and more.
Unexplained Weight Loss: When to See a Doctor
Losing 5% or more of body weight unintentionally in 6-12 months warrants evaluation. See thresholds, causes and the tests doctors run first.
White Spots on Nails: What Could Be Causing Them
Board-reviewed guide to leukonychia (white spots on nails) covering the 8 most common causes, how doctors diagnose them, when they signal systemic disease, and what treatments actually work.
White Spots on Nails: When to See a Doctor
White spots on nails (leukonychia) are usually harmless, but certain patterns signal systemic disease. Learn what causes them, when to worry, and how they are diagnosed and treated.
Yellow Eyes: Labs Your Doctor Will Order and What to Do Next
Yellow eyes (scleral icterus) signal elevated bilirubin. Learn which blood tests, imaging studies, and specialist referrals you need, plus when yellowing demands emergency care.
Yellow Skin but Not Jaundice? Causes Explained
Yellow skin without eye yellowing often means carotenoid pseudojaundice, not liver disease. True jaundice needs bilirubin above 2.5 mg/dL and affects the eyes first.
Tadalafil (Generic) Geriatric Dosing: Safe Use in Adults 65 and Older
Evidence-based guide to tadalafil dosing in older adults (65+), covering starting doses, renal adjustments, drug interactions, fall risk, and BPH considerations.
Tadalafil (Generic) Off-Label Uses with Evidence Levels
A guide to tadalafil's off-label applications beyond ED and BPH, graded by clinical evidence from RCTs, meta-analyses, and guideline endorsements.
Tadalafil (Generic) Dosing for Older Adults (50 to 64): Evidence-Based Guide
How to dose generic tadalafil for adults aged 50 to 64, including daily vs. on-demand protocols, drug interactions, cardiovascular screening, and BPH overlap.
Tadalafil Patent History and Generic Timeline: How Cialis Lost Exclusivity
A clinical deep-dive into tadalafil's patent expiration, Paragraph IV challenges, and the generic timeline from 2017 onward, with FDA and trial-cited evidence.
Tadalafil (Generic) Pharmacogenomics & Genetic Variability
How CYP3A4, CYP3A5, and PDE5A polymorphisms influence tadalafil metabolism, efficacy, and side-effect risk. Evidence-based guidance for clinicians considering pharmacogenomic testing.
Tadalafil (Generic) Pregnancy and Lactation Safety
Is tadalafil safe during pregnancy or breastfeeding? Review FDA labeling, animal reproductive data, human evidence, and clinical guidance for tadalafil in reproductive contexts.
Tadalafil (Generic) Real-World Evidence: Registry Data, Observational Studies, and Post-Market Outcomes
A clinical review of real-world evidence for generic tadalafil 2.5-20 mg across erectile dysfunction and BPH, including registry studies, claims analyses, and post-market safety data.
Tadalafil (Generic) Dosing in Renal Impairment
Evidence-based guide to tadalafil dose adjustments in kidney disease, covering mild, moderate, and severe renal impairment plus dialysis patients, with FDA label data and primary-source citations.
Tadalafil (Generic) Safety Signals and FDA Actions
Tadalafil has no boxed warning, but organic nitrates are contraindicated. The label's 48-hour figure applies only to life-threatening emergencies.
Does UnitedHealthcare Cover Tadalafil (Generic)?
UnitedHealthcare typically covers generic tadalafil on Tier 3 with prior authorization. Learn formulary placement, PA criteria, step therapy rules, appeal steps, and cost-saving strategies.
Tadalafil (Generic) Safety for Young Adults (18 to 29): What the Evidence Shows
A clinical review of tadalafil generic safety in men aged 18 to 29, covering dosing, side effects, cardiovascular risk, fertility, and long-term use considerations.
TB-500 Cost vs. Alternatives: Comparing Peptide Options for Tissue Repair
Why no TB-500 price comparison exists, its FDA and compounding status, and what the evidence does and does not show about this thymosin beta-4 fragment.
TB-500 Drug-Drug Interactions: What Clinicians and Patients Should Know
No TB-500 drug interactions have been documented, and FDA found no human studies of this thymosin beta-4 fragment, which is not approved.
TB-500 Food and Supplement Interactions: What Clinicians and Patients Should Know
A clinician-grade guide to TB-500 (thymosin beta-4 active fragment) interactions with foods, supplements, and nutraceuticals, including timing, safety signals, and evidence-based precautions.
TB-500 Safety in Geriatric Patients (65+): What Clinicians Should Know
Explains why TB-500 has no safety data for adults aged 65 and older, and what FDA found on its regulatory status and human evidence.
TB-500 History: From Thymosin Beta-4 to Regulatory Review
A history of TB-500, the synthetic thymosin beta-4 fragment, from calf thymus protein work to its 2003 synthesis and unapproved regulatory status.
TB-500 Manufacturing and Supply: What FDA Found
TB-500 has no approved or pharmacy-compounded product; this page covers online research-use supply, FDA and HHS actions in 2026, and its WADA status.
TB-500 Storage, Stability & Shelf Life: How to Keep Your Peptide Potent
Evidence-based guide to TB-500 (thymosin beta-4 fragment) storage conditions, reconstitution stability, shelf life data, and best practices for preserving peptide potency.
TB-500: Switching From or To Other Peptides in the Same Class
Evidence-based guide to switching TB-500 (thymosin beta-4 active fragment) protocols with BPC-157, GHK-Cu, and other tissue-repair peptides, including timing, dosing, and clinical considerations.
Egrifta (Tesamorelin) Geriatric (65+) Dosing
Evidence-based guide to tesamorelin dosing in adults 65 and older, covering pharmacokinetics, renal considerations, monitoring, and clinical pearls for prescribers managing HIV-associated lipodystrophy in geriatric patients.
Egrifta (Tesamorelin) Geriatric (65+) Safety
Evidence-based guide to tesamorelin safety in adults 65 and older, covering dose adjustments, renal monitoring, drug interactions, IGF-1 surveillance, and deprescribing considerations.
Egrifta (Tesamorelin) History and Development: From GHRH Analog Discovery to FDA Approval
A comprehensive clinical history of tesamorelin (Egrifta), the synthetic GHRH analog developed by Theratechnologies for HIV-associated lipodystrophy, covering mechanism of action, key trials, and regulatory milestones.
Egrifta (Tesamorelin) Monitoring Schedule: Labs & Exams
Evidence-based monitoring schedule for tesamorelin (Egrifta SV) therapy in HIV-associated lipodystrophy, including IGF-1, glucose, lipids, and imaging timelines.
Tesamorelin Dosing at 50–64: Adult Label, Missing Subgroup
An age-and-formulation audit for tesamorelin at ages 50–64, separating the adult EGRIFTA label from absent age-specific dosing and safety evidence.
Egrifta (Tesamorelin) Safety in Older Adults (50 to 64): What the Evidence Shows
A clinical review of tesamorelin (Egrifta) safety for adults aged 50 to 64, covering cardiovascular risk, IGF-1 monitoring, drug interactions, and age-specific adverse effects.
Egrifta (Tesamorelin) Dosing in Renal Impairment
Evidence-based guide to tesamorelin (Egrifta) dosing in patients with renal impairment, including pharmacokinetic considerations, GFR thresholds, monitoring parameters, and clinical recommendations for HIV-associated lipodystrophy.
Testosterone Cypionate Monitoring for Adults (30 to 49): Lab Schedule, Target Ranges, and Red Flags
Evidence-based monitoring protocol for testosterone cypionate therapy in men aged 30, 49, including lab timing, hematocrit thresholds, cardiovascular screening, and fertility preservation.
Does Aetna (CVS Health) Cover Testosterone Cypionate?
Aetna (CVS Health) covers testosterone cypionate for diagnosed male hypogonadism with prior authorization. Learn formulary tier, step therapy rules, PA criteria, appeal steps, and cost-saving strategies.
Testosterone Cypionate Food & Supplement Interactions
Evidence-based guide to foods, supplements, and nutrients that interact with testosterone cypionate, including effects on absorption, metabolism, and clinical outcomes.
Testosterone Cypionate in Adults 65 and Older: Safety Profile, Risks, and Monitoring
Evidence-based safety guide for testosterone cypionate use in geriatric men (65+), covering cardiovascular risk, prostate screening, polypharmacy, falls, and monitoring protocols.
Testosterone Mechanism of Action: Injection to Receptor
Testosterone cypionate forms an IM depot, releases free testosterone via esterases, binds AR, converts to DHT or estradiol, and suppresses the HPG axis.
Testosterone Cypionate Patent History and Generic Timeline
A clinical review of testosterone cypionate's patent history, generic availability, current formulations, and what prescribers and patients should know about access and cost in 2024 and beyond.
Can You Take Testosterone While Pregnant? No, It's Contraindicated
The Depo-Testosterone label lists pregnancy as a contraindication. It says testosterone may cause fetal harm and virilization of the female fetus.
Testosterone Cypionate Real-World Evidence: What Registries and RWE Studies Actually Show
A clinical review of real-world evidence for testosterone cypionate from patient registries, observational cohorts, and post-marketing studies, with PubMed-cited data on outcomes, safety, and long-term effects.
Testosterone Cypionate Regulatory Status: US, EU, Canada, and UK Rules Explained
A country-by-country breakdown of testosterone cypionate's prescription status, controlled-substance scheduling, and availability across the US, EU, Canada, and the UK.
Testosterone Cypionate Storage, Stability & Shelf Life
Evidence-based guide to testosterone cypionate storage conditions, chemical stability data, shelf life after opening, and proper handling to maintain potency and sterility.
Does TRICARE Cover Testosterone Cypionate?
TRICARE covers testosterone cypionate for diagnosed male hypogonadism. Learn about formulary tier, prior authorization requirements, step therapy, appeal options, and out-of-pocket costs for military beneficiaries.
Testosterone Cypionate Dosing for Young Adults (18-29): Evidence-Based Protocols
Clinical guide to testosterone cypionate dosing in men aged 18-29, covering starting doses, titration, fertility preservation with hCG, and monitoring schedules backed by endocrine society guidelines.
Testosterone Enanthate Safety in Adults (30 to 49): Risks, Monitoring, and Evidence
Evidence-based safety profile of testosterone enanthate for men aged 30, 49, covering cardiovascular risk, hematologic monitoring, fertility impact, and FDA-mandated warnings.
Does Aetna (CVS Health) Cover Testosterone Enanthate?
Aetna (CVS Health) covers testosterone enanthate for diagnosed male hypogonadism with prior authorization. Learn formulary tier, step therapy requirements, PA criteria, and how to appeal a denial.
Testosterone Enanthate Cost vs. Alternatives: A Class-Wide Price and Efficacy Comparison
Compare testosterone enanthate pricing against cypionate, undecanoate, topical gels, oral capsules, nasal gel, and pellets. Includes per-month costs, insurance coverage patterns, and clinical equivalence data.
Testosterone Enanthate: How to Safely Stop TRT
Evidence-based protocol for discontinuing testosterone enanthate, including tapering strategies, PCT options, HPTA recovery timelines, and monitoring labs.
Testosterone Enanthate Food & Supplement Interactions
Evidence-based guide to food and supplement interactions with testosterone enanthate, including effects on absorption, metabolism, and clinical outcomes.
Testosterone Enanthate in Adults 65 and Older: Safety Profile, Risks, and Monitoring
Evidence-based safety guide for testosterone enanthate use in men aged 65 and older, covering cardiovascular risk, polycythemia, falls, drug interactions, and monitoring protocols.
Testosterone Enanthate: History and Development
Testosterone enanthate is testosterone with an oil-soluble ester that releases slowly after injection. Drugs@FDA lists Delatestryl approval in 1953.
Testosterone Enanthate Manufacturing, Supply & Shortage History
A clinical deep-dive into testosterone enanthate manufacturing processes, supply chain dynamics, and the history of drug shortages affecting TRT patients in the United States.
Testosterone Enanthate Mechanism of Action: Full Pathway From Injection to Androgen Receptor
MD-level explanation of how testosterone enanthate works, from ester hydrolysis and depot release through androgen receptor binding, gene transcription, and downstream physiologic effects. PubMed-cited.
Does State Medicaid Cover Testosterone Enanthate?
State Medicaid coverage for testosterone enanthate varies widely. Learn which states cover it, prior authorization requirements, formulary tiers, appeal processes, and how to reduce out-of-pocket costs.
Does Medicare Advantage Cover Testosterone Enanthate?
Medicare Advantage plans generally cover testosterone enanthate for diagnosed male hypogonadism. Learn about formulary tiers, prior authorization requirements, step therapy, and how to appeal a denial.